BR112015021470A2 - conjugado de polímero para administração de um agente bioativo - Google Patents

conjugado de polímero para administração de um agente bioativo

Info

Publication number
BR112015021470A2
BR112015021470A2 BR112015021470A BR112015021470A BR112015021470A2 BR 112015021470 A2 BR112015021470 A2 BR 112015021470A2 BR 112015021470 A BR112015021470 A BR 112015021470A BR 112015021470 A BR112015021470 A BR 112015021470A BR 112015021470 A2 BR112015021470 A2 BR 112015021470A2
Authority
BR
Brazil
Prior art keywords
bioactive agent
polymer
conjugates
administration
polymer conjugate
Prior art date
Application number
BR112015021470A
Other languages
English (en)
Other versions
BR112015021470B1 (pt
Inventor
Sulistio Adrian
Craig Donohue Andrew
Blencowe Anton
John Tait Russell
Man Yee Ng Sarah
Lonsdale Birkett Stephen
Original Assignee
Polyactiva Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013900883A external-priority patent/AU2013900883A0/en
Application filed by Polyactiva Pty Ltd filed Critical Polyactiva Pty Ltd
Publication of BR112015021470A2 publication Critical patent/BR112015021470A2/pt
Publication of BR112015021470B1 publication Critical patent/BR112015021470B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

resumo "conjugado de polímero para administração de um agente bioativo" a presente invenção se relaciona em geral com conjugados polímero-agente bioativo para administração de um agente bioativo a um sujeito. os conjugados polímero-agente bioativo contêm frações de triazol na estrutura principal de polímero e uma fração bioativa selecionada de análogos da prostaglandina, ß-bloqueantes e suas misturas. a presente invenção se relaciona também com métodos para preparação dos conjugados de polímero usando reações químicas click, com conjugados monômero-agente bioativo adequados para preparação dos conjugados de polímero, e com produtos farmacêuticos compreendendo os conjugados de polímero para o tratamento de glaucoma.
BR112015021470-3A 2013-03-08 2014-03-07 Conjugado de polímero-agente bioativo, implante ocular compreendendo o mesmo e uso do referido conjugado BR112015021470B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013900883A AU2013900883A0 (en) 2013-03-08 Polymer conjugate for delivery of a bioactive agent
AU2013900883 2013-03-08
PCT/AU2014/000231 WO2014134689A1 (en) 2013-03-08 2014-03-07 Polymer conjugate for delivery of a bioactive agent

Publications (2)

Publication Number Publication Date
BR112015021470A2 true BR112015021470A2 (pt) 2017-07-18
BR112015021470B1 BR112015021470B1 (pt) 2022-11-01

Family

ID=51490501

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021470-3A BR112015021470B1 (pt) 2013-03-08 2014-03-07 Conjugado de polímero-agente bioativo, implante ocular compreendendo o mesmo e uso do referido conjugado

Country Status (16)

Country Link
US (2) US9572892B2 (pt)
EP (1) EP2964224A4 (pt)
JP (1) JP6509746B2 (pt)
KR (1) KR102210895B1 (pt)
CN (1) CN105358146B (pt)
AU (1) AU2014225305B2 (pt)
BR (1) BR112015021470B1 (pt)
CA (1) CA2902372C (pt)
CL (1) CL2015002462A1 (pt)
HK (1) HK1220117A1 (pt)
IL (1) IL241147A (pt)
MX (1) MX2015011874A (pt)
MY (1) MY181013A (pt)
NZ (1) NZ711392A (pt)
SG (1) SG11201507024VA (pt)
WO (1) WO2014134689A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507024VA (en) 2013-03-08 2015-10-29 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
JP6823067B2 (ja) * 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
EP3347052A4 (en) * 2015-09-11 2019-05-29 Polyactiva Pty Ltd POLYMERIC CONJUGATE WITH A BIOACTIVE ACTIVE SUBSTANCE
WO2017189953A1 (en) * 2016-04-29 2017-11-02 Children's Medical Center Corporation Poly(ketals) and related compositions and methods
EP3595670A4 (en) * 2017-03-14 2021-05-12 Polyactiva Pty Ltd DRUG-POLYMER CONJUGATE
US11696955B2 (en) 2017-03-14 2023-07-11 Polyactiva Pty Ltd Drug-polymer conjugate
US11207417B2 (en) 2017-03-14 2021-12-28 Polyactiva Pty Ltd Drug-polymer conjugate
EP3606559A1 (en) 2017-04-07 2020-02-12 Tambo, Inc. Bioorthogonal compositions
US10606274B2 (en) 2017-10-30 2020-03-31 Nio Usa, Inc. Visual place recognition based self-localization for autonomous vehicles
CN107892660A (zh) * 2017-12-08 2018-04-10 西安近代化学研究所 1‑叠氮乙酰氧基‑2,2‑双叠氮甲基‑3‑叠氮基丙烷化合物
WO2020013696A1 (en) * 2018-07-13 2020-01-16 Cristal Delivery B.V. Thiocycloheptyne derivatives and their use
US20220401455A1 (en) * 2019-09-19 2022-12-22 Polyactiva Pty Ltd Biodegradable drug-polymer conjugate
JP7451732B2 (ja) 2020-02-06 2024-03-18 オキュラ セラピューティクス，インコーポレイテッド 眼疾患を治療するための組成物及び方法
WO2021195163A1 (en) 2020-03-25 2021-09-30 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044797B (it) * 1974-10-15 1980-04-21 Ferruti Paolo Alti polimeri contenenti radicali prostaglandinici processo per la loro preparazione e loro impiego
JPH03220201A (ja) 1988-11-18 1991-09-27 Eisai Co Ltd プロスタグランジン類と多糖類の結合体
US5216115A (en) 1990-06-12 1993-06-01 Rutgers, The State University Of New Jersey Polyarylate containing derivatives of the natural amino acid L-tyrosine
US7122615B1 (en) 1998-09-10 2006-10-17 Rutgers, The State University Of New Jersey Polyanhydrides with therapeutically useful degradation products
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US8158590B2 (en) * 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
WO2008128193A1 (en) 2007-04-12 2008-10-23 Rutgers, The State University Of New Jersey Biodegradable polyanhydrides with natural bioactive molecules
EP2355853B1 (en) 2008-10-10 2016-12-07 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
WO2010141507A1 (en) * 2009-06-01 2010-12-09 Ablitech, Inc. Biomolecule-polymer conjugates and methods of making same
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012072117A1 (en) * 2010-11-30 2012-06-07 Tomtom International B.V. Methods and systems for obtaining location information
WO2012075117A2 (en) 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
EP2696899A4 (en) * 2011-04-12 2014-10-08 Polyactiva Pty Ltd PROSTAGLANDINE ANALOGUES CONJUGATED TO A POLYMER
JP5770559B2 (ja) 2011-08-04 2015-08-26 住友ゴム工業株式会社 タイヤ用ゴム組成物及びスタッドレスタイヤ
JP2013035802A (ja) * 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
SG11201507024VA (en) 2013-03-08 2015-10-29 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
US10113033B2 (en) 2013-03-08 2018-10-30 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent

Also Published As

Publication number Publication date
KR20150126025A (ko) 2015-11-10
IL241147A (en) 2017-11-30
US9572892B2 (en) 2017-02-21
BR112015021470B1 (pt) 2022-11-01
KR102210895B1 (ko) 2021-02-02
CA2902372C (en) 2021-06-15
US20170216308A1 (en) 2017-08-03
SG11201507024VA (en) 2015-10-29
IL241147A0 (en) 2015-11-30
MX2015011874A (es) 2016-01-25
CN105358146B (zh) 2019-11-29
MY181013A (en) 2020-12-16
EP2964224A1 (en) 2016-01-13
JP6509746B2 (ja) 2019-05-08
JP2016515099A (ja) 2016-05-26
EP2964224A4 (en) 2016-11-30
HK1220117A1 (zh) 2017-04-28
NZ711392A (en) 2020-05-29
AU2014225305A1 (en) 2015-09-10
AU2014225305B2 (en) 2019-01-31
CL2015002462A1 (es) 2016-02-05
US20160000929A1 (en) 2016-01-07
US10111886B2 (en) 2018-10-30
CN105358146A (zh) 2016-02-24
WO2014134689A1 (en) 2014-09-12
CA2902372A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
MX2022006107A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015031903A2 (pt) composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112012004806B8 (pt) composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112014026703A2 (pt) inibidores de dna-pk
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
IN2015DN03219A (pt)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112014012056A8 (pt) compostos farmacêuticos
WO2015038533A3 (en) Sodium channel modulators for the treatment of pain and diabetes
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS